Sector News

Mylan offers $28 billion for Perrigo

April 9, 2015
Life sciences
Mylan has made an offer to buy Dublin, Ireland-based Perrigo for more than $28 billion, as the current acquisitions trend in pharma continues at pace.
 
The company said it would pay $205 in a combination of cash and Mylan stock for each Perrigo share, which represents a greater than 25% premium to the latter’s stock price as of April 3, 2015.
 
According to Mylan, the marriage of these “highly complementary businesses” would create “a diversified, global pharmaceutical leader with an unmatched commercial and operating platform and a unique, one-of-a-kind profile”. 
 
In a letter to Perrigo’s chairman, Mylan chief Robert Coury noted that the proposed transaction “makes compelling strategic sense” and would result in a combined company with “a very strong financial profile”, with annual sales of more than $15 billion.
 
Perrigo confirmed receipt of the offer, and noted that its board will now meet to discuss the proposal.
 
Mylan’s move comes just months after it relocated its headquarters from the US to The Netherlands as part of its purchase of Abbott’s main branded generics business, thereby considerably cutting its tax bill.
 
By Selina McKee
 
Source: Pharma Times
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach